Bevacizumab

Therapeutic Bevacizumab antibody from the original Avastin® commercial drug and biosimilars.

Reference Standard as Aliquots

Avastin®
Filters Sort results
Reset Apply
Product Batch
Therapeutic Expiry Date
Brand & Origin
Amount per Aliquot
Select Quantity
Discount
Price per Aliquot
Bevacizumab B7219H04
2018.06
Avastin®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B7223H06
2018.09
Avastin®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B7223H17
2018.09
Avastin®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B7226H07
2018.12
Avastin®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B7230H14
2019.03
Avastin®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B7234H02
2019.08
Avastin®
LV
2 mg
Product details
Max: 35
Min: 1
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B8020H05
2019.10
Avastin®
DE
2 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab B8800H28
2021.03
Avastin®
LT
2 mg
Product details
Max: 4
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab H0152B21
2017.09
Avastin®
DE
3 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
267,00 € /aliquot
Add to Wishlist
Bevacizumab H0156B21
2018.03
Avastin®
DE
3 mg
Product details
Max: 10
Min: 2
Step: 1
Unit: aliquot(s)
267,00 € /aliquot
Add to Wishlist
Bevacizumab H0340H03
2024.07
Avastin®
LT
2 mg
Product details
Max: 7
Min: 2
Step: 1
Unit: aliquot(s)
212,00 € /aliquot
Add to Wishlist
Bevacizumab H0403H07
2027.03
Avastin®
DE
2 mg
Product details
Max: 30
Min: 2
Step: 1
Unit: aliquot(s)
167,00 €/aliquot
Add to Wishlist

Biosimilars as Aliquots​

Zirabev®, Oyavas®, Alymsys®,Aybintio®, Abevmy®, Vegzelma®
Filters Sort results
Reset Apply
Product Batch
Therapeutic Expiry Date
Brand & Origin
Amount per Aliquot
Select Quantity
Discount
Price per Aliquot
Bevacizumab
tbd; product is not in stock - minimum order quantity applies
Zirabev®
DE
2 mg
View details
205,00 € /aliquot
Bevacizumab
tbd; product is not in stock - minimum order quantity applies
Oyavas®
DE
2 mg
View details
203,00 € /aliquot
Bevacizumab
tbd; product is not in stock - minimum order quantity applies
Alymsys®
DE
2 mg
View details
203,00 € /aliquot
Bevacizumab
tbd; product is not in stock - minimum order quantity applies
Aybintio®
DE
2 mg
View details
203,00 € /aliquot
Bevacizumab
tbd; product is not in stock - minimum order quantity applies
Abevmy®
DE
2 mg
View details
213,00 € /aliquot
Bevacizumab
tbd; product is not in stock - minimum order quantity applies
Vegzelma®
DE
2 mg
View details
204,00 € /aliquot

Access Batch Specific Analytical Information

Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API). ​

Request an Offer​

and Download a Sample Report​

1. Choose your method(s) of interest
2. Provide your contact details
3. Send us your request and receive a downloadable sample report


Please provide your contact information


send us your inquiry and download a free sample file


Product Information

Here you will find the product information for the reference product.

Avastin® / Bevacizumab Reference Product

Drug nameAvastin®
INNBevacizumab
API typeBevacizumab is a recombinant humanised monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells.
Pharmacotherapeutic group
Antineoplastic and immunomodulating agents, antineoplastic agents, other antineoplastic agents, monoclonal antibodies
ATC code
L01X C07
Target of antibody
VEGF-A; Synonyms: vegf, vegfa, wu:fj82c06, VEGF, vegf-a, vpf, vefg, VPF, eVEGF120, eVEGF164, MVCD1, Vegf, Vegf120, Vegf164, Vegf188, Vpf, VEGF164
General functionInhibits vascular endothelial growth factor A and is commonly used to treat various cancers, including colorectal, lung, breast, kidney, and glioblastomas
Short descriptionBevacizumab is comprised of a tetramer of two heavy and two light chains with one N-glycosylation site per heavy chain Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis
and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and
KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF
regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the
formation of new tumour vasculature, thereby inhibiting tumour growth.
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Administration of bevacizumab or its parental murine antibody to xenotransplant models of cancer in
nude mice resulted in extensive anti-tumour activity in human cancers, including colon, breast,
pancreas and prostate. Metastatic disease progression was inhibited and microvascular permeability
was reduced.
MBC and EBC patients had similar PK parameters (e.g. clearance (CL), the central compartment volume (Vc)) and population-predicted steady-state exposures (Cmin, Cmax and AUC). Linear clearance was 0.136 L/day for MBC, 0.112 L/day for EBC and 0.176 L/day for AGC. The non-linear elimination parameter values were 8.81 mg/day for the maximum elimination rate (Vmax) and 8.92 μg/mL for the Michaelis-Menten constant (Km) for the MBC, EBC, and AGC patients. The central compartment volume was 2.62 L for patients with MBC and EBC and 3.63 L for patients with AGC.
In the final population PK model, in addition to primary tumor type, body-weight, serum aspartate aminotransferase and albumin were identified as a statistically significant covariates affecting the exposure of trastuzumab. However, the magnitude of effect of these covariates on trastuzumab exposure suggests that these covariates.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)n/a
Original license holder
Marketing authorisation numbers
EU/1/04/300/001 - 002
Marketing authorisation holder
Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom
Name of the manufacturer of the biological active substance
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990
USA

Genentech, Inc.
1 Antibody Way
Oceanside, CA 92056
USA
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
CH-4070 Basel
Switzerland

Roche Singapore Technical Operations, Pte. Ltd.
10 Tuas Bay Link
Singapore 637394
Singapore
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barrell-Str. 1,
D-79639 Grenzach-Wyhlen
Germany
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Trehalose dihydrate
Sodium phosphate
Polysorbate 20
Water for injections

Support

Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!

Ready to simplify your sourcing?

Here’s how to get started:

Select Your Licensed Molecules

Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!

Get a Quote

Receive a confidential, non-binding quote for the molecule(s) you choose.

Get Qualified & We Deliver

Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.

Explore our Shop

Do you have a question you'd like to ask us?

Here’s how to get started:

Reach out to our team - we'd be happy to help you!

+49 (0) 30 959 99 8832
info@evidentic.com

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.